John Paulson Holdings 13F: Latest Paulson & Co Portfolio Changes
Paulson & Co. Famous for the greatest trade ever (2008 subprime). John Paulson became a billionaire by using credit default swaps to short the US housing market before the 2008 financial crisis, a trade chronicled in the book 'The Greatest Trade Ever'.
As of the latest Q1 2026 13F filing, John Paulson (managing Paulson & Co) reported a public portfolio value of $3.1B with 9 positions. This page tracks latest holdings, latest 13F changes, top buys, top sells, and top holdings from the public filing. The top recent buy was THM. The top recent sell was MDGL.
Open interactive portfolioLatest 13F portfolio changes
John Paulson holdings 13F summary: the latest Paulson & Co portfolio changes show top holdings including PERPETUA RESOURCES, MADRIGAL PHARMACEUTICALS, ACADIAN ASSET MANAGEMENT, BAUSCH HEALTH COS, and NOVAGOLD RESOURCES, reported top buys such as INTERNATIONAL TOWER HILL MIN, THRYV HLDGS, and AMICUS THERAPEUTIC, and top sells or reductions such as MADRIGAL PHARMACEUTICALS and SOLSTICE ADVANCED MATLS.
Latest filing metadata: quarter Q1 2026; report date 2026-03-31; filing date 2026-05-15; disclosure source SEC 13F.
John Paulson 13F portfolio and latest holdings overview
John Paulson's Q1 2026 13F holdings show Paulson & Co reporting 9 positions with a disclosed portfolio value of $3.1B. For readers searching John Paulson 13F holdings, John Paulson portfolio, Paulson & Co holdings, or latest 13F changes, the latest top holdings include PERPETUA RESOURCES, MADRIGAL PHARMACEUTICALS, ACADIAN ASSET MANAGEMENT, BAUSCH HEALTH COS, and NOVAGOLD RESOURCES.
The three largest reported positions add up to roughly 66.2%, which helps readers judge portfolio concentration rather than just headline AUM. The largest reported sector exposure is Energy at 37.1% of the disclosed portfolio. This makes the page useful for comparing the manager's actual disclosed exposure with market narratives around the same names.
The latest change data highlights reported buys such as INTERNATIONAL TOWER HILL MIN, THRYV HLDGS, and AMICUS THERAPEUTIC and reported reductions or exits such as MADRIGAL PHARMACEUTICALS and SOLSTICE ADVANCED MATLS. Those changes should be read as historical disclosure signals, not as real-time trade alerts.
The filing metadata lists report date 2026-03-31, filing date 2026-05-15, SEC accession 0001013594-26-000611. SEC 13F reports are normally published up to 45 days after quarter end, so the data is best used to understand institutional positioning after the fact rather than to infer today's exact portfolio.
John Paulson portfolio analytics
the top five positions account for 86.8% of disclosed value; the largest sector exposure is Energy at 37.1%; reported buy and sell activity implies roughly 33.7% turnover this period; cost-basis P&L across 7 tracked positions averages 138.7% (4/6 currently in profit).
Top reported holdings
| Holding | Reported value | Weight | Quarter change |
|---|---|---|---|
| PPTA whale holders PERPETUA RESOURCES CORP | $909.6M | 29.2% | Held |
| MDGL whale holders MADRIGAL PHARMACEUTICALS INC | $728.8M | 23.4% | Reduced |
| AAMI whale holders ACADIAN ASSET MANAGEMENT INC | $421.4M | 13.5% | Held |
| BHC whale holders BAUSCH HEALTH COS INC | $395.6M | 12.7% | Held |
| NG whale holders NOVAGOLD RESOURCES INC | $244.6M | 7.9% | Held |
| THM whale holders INTERNATIONAL TOWER HILL MIN | $229.0M | 7.4% | Increased |
| AEM whale holders AGNICO EAGLE MINES LTD | $159.0M | 5.1% | Held |
| THRY whale holders THRYV HLDGS INC | $23.1M | 0.7% | Increased |
| FOLD whale holders AMICUS THERAPEUTIC | $468.5K | 0.0% | New |
Top buys
- THM whale holders — INTERNATIONAL TOWER HILL MIN ($229.0M)
- THRY whale holders — THRYV HLDGS INC ($23.1M)
- FOLD whale holders — AMICUS THERAPEUTIC ($468.5K)
Top sells
- MDGL whale holders — MADRIGAL PHARMACEUTICALS INC ($728.8M)
- SOLS whale holders — SOLSTICE ADVANCED MATLS INC ($67.8M)
Allocation
- Energy: 37.1%
- Health Care: 36.1%
- Other: 21.7%
- Materials: 5.1%
Data notes
Report date: 2026-03-31
Disclosure source: SEC 13F
SEC 13F filings are delayed public disclosures and do not include every asset class, short positions, or real-time trades.
Related investor portfolios
- Horizon Kinetics 13F holdings and Horizon Kinetics Asset Management portfolio changes — Horizon Kinetics Asset Management
- Lee Ainslie 13F holdings and Maverick Capital portfolio changes — Maverick Capital
- John Griffin 13F holdings and Blue Ridge Capital portfolio changes — Blue Ridge Capital
- Peter Kolchinsky 13F holdings and RA Capital Management portfolio changes — RA Capital Management
- Carl Icahn 13F holdings and Icahn Enterprises portfolio changes — Icahn Enterprises
- Nelson Peltz 13F holdings and Trian Fund Management portfolio changes — Trian Fund Management
- Seth Klarman 13F holdings and Baupost Group portfolio changes — Baupost Group
- Robert Robotti 13F holdings and Robotti & Co portfolio changes — Robotti & Co
Learn more in Whale Analyzer Academy
Learn more in Whale Analyzer Academy:
Frequently asked questions
John Paulson 13F Holdings
The Q1 2026 13F profile for John Paulson and Paulson & Co shows 9 reported positions, $3.1B in disclosed portfolio value, and top holdings including PERPETUA RESOURCES, MADRIGAL PHARMACEUTICALS, ACADIAN ASSET MANAGEMENT, BAUSCH HEALTH COS, and NOVAGOLD RESOURCES.
What is John Paulson buying? Latest 13F changes
The latest tracked change data for John Paulson highlights reported buys such as INTERNATIONAL TOWER HILL MIN, THRYV HLDGS, and AMICUS THERAPEUTIC and reported sells or reductions such as MADRIGAL PHARMACEUTICALS and SOLSTICE ADVANCED MATLS.
Paulson & Co top holdings
Paulson & Co top holdings are summarized from public disclosures with reported values, weights, portfolio concentration, top buys, top sells, and filing metadata where available.
John Paulson buys and sells
Use the top buys and top sells sections above to compare John Paulson's reported additions, reductions, exits, and latest portfolio activity against other tracked investors.
How delayed is John Paulson's 13F data?
SEC Form 13F requires institutional investment managers with $100M+ in US equities to disclose their holdings quarterly. Read our comprehensive 13F guide for timing, coverage, and limitations. Read the Whale Analyzer 13F guide.